29.01
8.04%
2.16
Dopo l'orario di chiusura:
29.03
0.02
+0.07%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BEAM Giù?
Forum
Previsione
Beam Therapeutics Inc Borsa (BEAM) Ultime notizie
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation - Simply Wall St
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.
Beam Therapeutics (BEAM) Stock Dips Amid Biotech Sector Decline - GuruFocus.com
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Beam Therapeutics CEO to Present at J.P. Morgan Healthcare Conference: Precision Gene Editing Spotlight - StockTitan
State Street Corp Purchases 437,402 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Decline in Short Interest - MarketBeat
Beam Therapeutics' SWOT analysis: base editing pioneer faces competitive gene therapy market - Investing.com
Beam Therapeutics' SWOT analysis: base editing pioneer faces competitive gene therapy market By Investing.com - Investing.com South Africa
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains - AOL
Brokers Issue Forecasts for BEAM FY2024 Earnings - MarketBeat
Beam Therapeutics announces new data from BEACON Phase 1/2 trial of BEAM-101 - MSN
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up - MSN
Why Beam Therapeutics (BEAM) Is the Worst ARK Stock to Buy According to Short Sellers - MSN
Beam Therapeutics (NASDAQ:BEAM) Rating Increased to Hold at Cantor Fitzgerald - MarketBeat
10 Worst ARK Stocks To Buy According to Short Sellers - Insider Monkey
Beam Therapeutics shares hold Outperform amid clinical data By Investing.com - Investing.com Canada
Beam Therapeutics shares hold Outperform amid clinical data - Investing.com
Beam Therapeutics Advances BEAM-101 Therapy for Sickle Cell - TipRanks
ASH: Beam’s Base Editor Efficacy In Sickle Cell Disease Holds Up - News & Insights
Beam Therapeutics Achieves Breakthrough in Sickle Cell Treatment with Promising ESCAPE Platform Data - StockTitan
Beam Therapeutics Presents New Non-human Primate (NHP) Data - GlobeNewswire
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for - The Bakersfield Californian
Charles Schwab Investment Management Inc. Boosts Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Stock Price Up 8.6%Here's Why - MarketBeat
BEAMBeam Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting - The Manila Times
Beam Therapeutics Announces New Data from BEACON Phase 1/2 - GlobeNewswire
Beam Therapeutics Reports Breakthrough Clinical Data for Sickle Cell Gene Therapy BEAM-101 - StockTitan
20,800 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Acquired by Polar Asset Management Partners Inc. - MarketBeat
Beam Therapeutics Inc. Appoints Sravan K. Emany as Chief Financial Officer, Effective December 19, 2024 - Marketscreener.com
Beam Therapeutics Names Sravan K. Emany as CFO - TipRanks
Beam Therapeutics names Sravan K. Emany as new CFO - Investing.com
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer - The Manila Times
Beam Therapeutics Names Former Ironwood CFO & Banking Veteran Sravan Emany as New Finance Chief - StockTitan
Tom Jede - The Business Journals
Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report? - Yahoo Finance
Redmile Group LLC Has $39.47 Million Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics adds Merck executive to board By Investing.com - Investing.com Canada
Erste Asset Management GmbH Makes New $544,000 Investment in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Sold by Fmr LLC - MarketBeat
Beam Therapeutics Inc. Announces the Appointment of Chirfi Guindo to Its Board of Directors - Marketscreener.com
Beam Therapeutics adds Merck executive to board - Investing.com
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader - The Manila Times
Beam Therapeutics Expands its Board of Directors with - GlobeNewswire
Beam Therapeutics Strengthens Board with Merck's Chief Marketing Officer Chirfi Guindo - StockTitan
Beam Therapeutics Breaks Below 200-Day Moving AverageNotable for BEAM - Nasdaq
Walleye Capital LLC Raises Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
(BEAM) Trading Report - Stock Traders Daily
20,892 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Acquired by Intech Investment Management LLC - MarketBeat
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):